Diagnostic Evaluation
Though most women with PMB will have atrophic vulvovaginitis or some other benign underlying cause, all women with PMB should be evaluated to rule out endometrial cancer, since 15-20% of women with this symptom will have the disease. The risk of harbouring endometrial cancer increases with age from a low of 15% in the immediately postmenopausal cohort to 50% in patients 80 years or older.
Initial evaluation should include a relevant history and physical examination, which must include a pelvic examination. An endometrial biopsy should be performed and any obvious lesion of the cervix or vagina should be biopsied directly. Endocervical curettage (ECC) should be considered if there is clinical concern regarding the possibility of cancer within the endocervical canal.
Endometrial sampling should be routinely considered for patients with PMB to rule out endometrial cancer.
Pelvic ultrasound can occasionally be useful as an adjunct to pelvic examination and endometrial sampling in the evaluation of women with PMB. This test is most useful in women where adequate endometrial sampling is not feasible without invasive methods (ie D+C +/- hysteroscopy). Ultrasound performed using an endovaginal probe can serve two purposes: to rule out the presence of other pelvic pathology not detected on pelvic examination (e.g. ovarian neoplasms) and to directly measure the endometrial thickness as a surrogate for the likelihood of an underlying endometrial carcinoma. An endometrial thickness of 5mm or more is considered abnormal. Although women with a thin endometrium rarely have an underlying type I endometrial cancer, women with type II endometrial cancer may have an endometrial thickness less than 5mm. A thickened endometrium is not always indicative of an underlying endometrial cancer, as [...] may result in an apparent thickened endometrium on ultrasound. As a result of this lack of diagnostic sensitivity and specificity, ultrasound is not acceptable as an alternative to pelvic examination or endometrial sampling for ruling out endometrial cancer in patients with PMB.
Answer
large endometrial polyps, submucous fibroids, characteristic tamoxifen effects (subendothelial cystic hyperplasia), or adenomyosis
Tags
#obgyn
Question
Diagnostic Evaluation
Though most women with PMB will have atrophic vulvovaginitis or some other benign underlying cause, all women with PMB should be evaluated to rule out endometrial cancer, since 15-20% of women with this symptom will have the disease. The risk of harbouring endometrial cancer increases with age from a low of 15% in the immediately postmenopausal cohort to 50% in patients 80 years or older.
Initial evaluation should include a relevant history and physical examination, which must include a pelvic examination. An endometrial biopsy should be performed and any obvious lesion of the cervix or vagina should be biopsied directly. Endocervical curettage (ECC) should be considered if there is clinical concern regarding the possibility of cancer within the endocervical canal.
Endometrial sampling should be routinely considered for patients with PMB to rule out endometrial cancer.
Pelvic ultrasound can occasionally be useful as an adjunct to pelvic examination and endometrial sampling in the evaluation of women with PMB. This test is most useful in women where adequate endometrial sampling is not feasible without invasive methods (ie D+C +/- hysteroscopy). Ultrasound performed using an endovaginal probe can serve two purposes: to rule out the presence of other pelvic pathology not detected on pelvic examination (e.g. ovarian neoplasms) and to directly measure the endometrial thickness as a surrogate for the likelihood of an underlying endometrial carcinoma. An endometrial thickness of 5mm or more is considered abnormal. Although women with a thin endometrium rarely have an underlying type I endometrial cancer, women with type II endometrial cancer may have an endometrial thickness less than 5mm. A thickened endometrium is not always indicative of an underlying endometrial cancer, as [...] may result in an apparent thickened endometrium on ultrasound. As a result of this lack of diagnostic sensitivity and specificity, ultrasound is not acceptable as an alternative to pelvic examination or endometrial sampling for ruling out endometrial cancer in patients with PMB.
Answer
?
Tags
#obgyn
Question
Diagnostic Evaluation
Though most women with PMB will have atrophic vulvovaginitis or some other benign underlying cause, all women with PMB should be evaluated to rule out endometrial cancer, since 15-20% of women with this symptom will have the disease. The risk of harbouring endometrial cancer increases with age from a low of 15% in the immediately postmenopausal cohort to 50% in patients 80 years or older.
Initial evaluation should include a relevant history and physical examination, which must include a pelvic examination. An endometrial biopsy should be performed and any obvious lesion of the cervix or vagina should be biopsied directly. Endocervical curettage (ECC) should be considered if there is clinical concern regarding the possibility of cancer within the endocervical canal.
Endometrial sampling should be routinely considered for patients with PMB to rule out endometrial cancer.
Pelvic ultrasound can occasionally be useful as an adjunct to pelvic examination and endometrial sampling in the evaluation of women with PMB. This test is most useful in women where adequate endometrial sampling is not feasible without invasive methods (ie D+C +/- hysteroscopy). Ultrasound performed using an endovaginal probe can serve two purposes: to rule out the presence of other pelvic pathology not detected on pelvic examination (e.g. ovarian neoplasms) and to directly measure the endometrial thickness as a surrogate for the likelihood of an underlying endometrial carcinoma. An endometrial thickness of 5mm or more is considered abnormal. Although women with a thin endometrium rarely have an underlying type I endometrial cancer, women with type II endometrial cancer may have an endometrial thickness less than 5mm. A thickened endometrium is not always indicative of an underlying endometrial cancer, as [...] may result in an apparent thickened endometrium on ultrasound. As a result of this lack of diagnostic sensitivity and specificity, ultrasound is not acceptable as an alternative to pelvic examination or endometrial sampling for ruling out endometrial cancer in patients with PMB.
Answer
large endometrial polyps, submucous fibroids, characteristic tamoxifen effects (subendothelial cystic hyperplasia), or adenomyosis
If you want to change selection, open document below and click on "Move attachment"
Dx eval of postmenopausal bleeding n endometrium rarely have an underlying type I endometrial cancer, women with type II endometrial cancer may have an endometrial thickness less than 5mm. A thickened endometrium is not always indicative of an underlying endometrial cancer, as <span>large endometrial polyps, submucous fibroids, characteristic tamoxifen effects (subendothelial cystic hyperplasia), or adenomyosis may result in an apparent thickened endometrium on ultrasound. As a result of this lack of diagnostic sensitivity and specificity, ultrasound is not acceptable as an alternative to pelv
Summary
status
not learned
measured difficulty
37% [default]
last interval [days]
repetition number in this series
0
memorised on
scheduled repetition
scheduled repetition interval
last repetition or drill
Details
No repetitions
Discussion
Do you want to join discussion? Click here to log in or create user.